Abstracts and Publications
A Phase 1/2 Dose Escalation and Cohort Expansion Study of AU-007, a Human Monoclonal Antibody (mAb) That Binds to IL-2 and Inhibits CD25 Binding, Plus Low-Dose Aldesleukin in Advanced Solid Tumors
McKean M, Frentzas S, Rasco D, et al.
Poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 2024
Determination of the phase 2 dose of AU-007, an AI-designed human monoclonal antibody that redirects IL-2 to T effector cells
Wyant T, Rasco D, McKean M, et al.
Poster presentation at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, October 2024
Updated results of a phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors
Rasco D, McKean M, Haydon A, et al.
Poster presentation at the American Society of Clinical Oncology (ASCO), June 2024
A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: Interim results from dose escalation (NCT05267626)
Frentzas S, Ahern E, Weickhardt A, et al.
Poster presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 2023
Preliminary pharmacodynamic evaluation of AU-007 in a phase 1a dose escalation trial for solid tumors (NCT05267626)
Vasselli J, Ahern E, Frentzas S, et al.
Poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 2023
Negative Feedback Expansion of Tregs Caused by Endogenous IL-2 Limits the Activity of IL-2-based Therapies
Amit I, Levitin N, Gadrich M, et al.
Peer-reviewed article in Journal of Cancer Immunology, J Cancer Immunol. 2023;5(1):29-39
Initial results from dose escalation of a phase 1/2, first-in-human, open label study of AU-007, a monoclonal antibody that binds to IL-2 and prevents its binding to CD25, in patients with solid tumors
Vasselli J, De Souza P, Frentzas S, et al.
Poster presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 2022
Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors
Vasselli J, De Souza P, Frentzas S, et al.
Poster presentation at the American Society of Clinical Oncology (ASCO), June 2022
AU-007, a computationally designed human antibody to the CD25-interacting domain of IL-2, demonstrates strong activity in murine syngeneic tumors in combination with IL-2 and PD-1 or PD-L1 antibodies
Amit I, Levin I, Wyant T, et al.
Preclinical poster, March 2022
AU-007, a computationally designed human antibody, mediates human immune activation by endogenous IL-2, while uniquely breaking the IL-2 negative feedback loop and preventing Treg expansion
Amit I, Levin I, Wyant T, et al.
Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 2021
Computationally Designed Antibodies Unlocking the Body’s Own IL-2 to Fight Cancer
Yanay Ofran, Ph.D.
Poster presentation video at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 2021
